title: N-acetylcysteine in bulimia nervosa--open-label trial.
abstract: The objective of this 12-week open-label flexible-dose study was to preliminarily assess the effectiveness of N-acetylcysteine (NAC) in bulimia nervosa (BN). The primary outcome was binge-purge episode frequency. Eight individuals with BN by DSM-IV criteria received NAC, but only two completed the study. NAC was not associated with significant reductions in frequency of binge-purge episodes or measures of clinical severity, eating, or mood pathology. In this trial, NAC was ineffective in BN and was associated with a high discontinuation rate.
authors.affiliation: Lindner Center of HOPE, Mason, OH 45040, USA. anna.guerdjikova@lindnercenter.org
authors.forename: Anna I
authors.initials: AI
authors.lastname: Guerdjikova
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Blom
authors.forename: Nicole
authors.initials: N
authors.lastname: Mori
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D056912:Binge-Eating Disorder / Q000188:drug therapy*; D052018:Bulimia Nervosa / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000111:Acetylcysteine